Ocular Events w ith   Mirvetuximab  Show No Impact on QoL in Ovarian Cancer https://tinyurl.com/4zbpp67k One of the more exciting developments in ovarian cancer treatment has been the FDA approval of an antibody drug combination called  E lahere   in the treatment of platinum resistant ovarian cancer . This group of patients are especially difficult to treat with a poor  disease-free  survival of aroun d  4   months. Results from the MIRASOL trial suggest an increase  to 6   months . Elahere  is  a targeted treatment for women with  ovarian  cancer wh ich   demonstrate  Folate Receptor 𝛂  expression (about 80%). One of the important adverse effects is loss of visual acuity . This is seen in 50% of patients, it develops with in   4 to 5 weeks of  commencing  treatment. The cause is inflammatory change due to local action of the drug and  subsequent  chronic  formation of mi...

Risk-Reduction Surgery Benefit in Non-BRCA Ovarian Cancer https://tinyurl.com/2mnd5c9y Risk reduction surgery has been promoted as a means of avoiding ovarian cancer. Most studies have concentrated on removal of fallopian tubes for women who are at high risk, especially those who carry the BRCA or Lynch mutation. Some centres have extended this for all women and suggested that additional surgery, to remove the fallopian tubes, be added to other abdominal surgical procedures. Any extra intervention will increase  operative  risk. This prospective study of 142 non-BRCA women at low risk, looks at the surgical specimen, and compares the evidence, of pre-cancer change with a similar control group of 388 women, who had the same surgery for risk reduction, in the presence of a hazardous mutation. Results from the study show similar rates of normal appearance at about 95%. No evidence of pre-cancer change was found in non BRCA women whereas 3% of specimen removed from BRCA +ve women ...